Literature DB >> 24293408

Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription.

Hai-Bo Yan1, Xue-Fei Wang, Qian Zhang, Zhao-Qing Tang, Ying-Hua Jiang, Hui-Zhi Fan, Yi-hong Sun, Peng-Yuan Yang, Feng Liu.   

Abstract

The chromatin remodeling gene AT-rich interactive domain-containing protein 1A (ARID1A) encodes the protein BAF250a, a subunit of human SWI/SNF-related complexes. Recent studies have identified ARID1A as a tumor suppressor. Here, we show that ARID1A expression is reduced in gastric cancer (GC) tissues, which are significantly associated with local lymph node metastasis, tumor infiltration and poor patient prognosis. ARID1A silencing enforces the migration and invasion of GC cells, whereas ectopic expression of ARID1A inhibits migration. The adhesive protein E-cadherin is remarkably downregulated in response to ARID1A silencing, but it is upregulated by ARID1A overexpression. E-cadherin overexpression significantly inhibits GC cell migration and invasion, whereas CDH1 (coded E-cadherin) silencing promotes migration. Restored expression of CDH1 in ARID1A-silenced cell lines restores the inhibition of cell migration. Luciferase reporter assays and chromatin immunoprecipitation indicate that the ARID1A-associated SWI/SNF complex binds to the CDH1 promoter and modulates CDH1 transcription. ARID1A knockdown induces evident morphological changes of GC cells with increased expression of mesenchymal markers, indicating an epithelial-mesenchymal transition. ARID1A silencing does not alter the level of β-catenin but induces a subcellular redistribution of β-catenin from the plasma membrane to the cytoplasm and nucleus. Immunohistochemical studies demonstrate that reduced expression of E-cadherin is associated with local lymph node metastasis, tumor infiltration and poor clinical prognosis. ARID1A and E-cadherin expression show a strong correlation in 75.4% of the analyzed GC tissues. They are synergistically downregulated in 23.5% of analyzed GC tissues. In conclusion, ARID1A targets E-cadherin during the modulation of GC cell migration and invasion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24293408     DOI: 10.1093/carcin/bgt398

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  63 in total

1.  Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.

Authors:  Anca Nastase; Jin Yao Teo; Hong Lee Heng; Cedric Chuan Young Ng; Swe Swe Myint; Vikneswari Rajasegaran; Jia Liang Loh; Ser Yee Lee; London Lucien Ooi; Alexander Yaw Fui Chung; Pierce Kah Hoe Chow; Peng Chung Cheow; Wei Keat Wan; Rafy Azhar; Avery Khoo; Sam Xin Xiu; Syed Muhammad Fahmy Alkaff; Ioana Cutcutache; Jing Quan Lim; Choon Kiat Ong; Vlad Herlea; Simona Dima; Dan G Duda; Bin Tean Teh; Irinel Popescu; Tony Kiat Hon Lim
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  ARID1A knockdown triggers epithelial-mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma.

Authors:  Keerakarn Somsuan; Paleerath Peerapen; Wanida Boonmark; Sirikanya Plumworasawat; Ratirath Samol; Natthiya Sakulsak; Visith Thongboonkerd
Journal:  FASEB J       Date:  2019-08-21       Impact factor: 5.191

3.  ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and apoptosis.

Authors:  Yi Zhang; Xiaoman Xu; Meng Zhang; Xue Bai; Hui Li; Liang Kan; Huiyan Niu; Ping He
Journal:  Tumour Biol       Date:  2014-02-26

Review 4.  Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.

Authors:  Yu Sunakawa; Heinz-Josef Lenz
Journal:  Curr Treat Options Oncol       Date:  2015-04

5.  Inhibition of perillyl alcohol on cell invasion and migration depends on the Notch signaling pathway in hepatoma cells.

Authors:  Yong Ma; Jianmin Bian; Feng Zhang
Journal:  Mol Cell Biochem       Date:  2015-10-17       Impact factor: 3.396

Review 6.  The epigenetic landscape of renal cancer.

Authors:  Mark R Morris; Farida Latif
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

7.  HEPACAM inhibited the growth and migration of cancer cells in the progression of non-small cell lung cancer.

Authors:  Huanzhang Shao; Yinjie Gu; Junli Ding; Peihua Lu; Tingyan Ruan; Wenbin Lu
Journal:  Tumour Biol       Date:  2015-09-22

8.  Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.

Authors:  Hiroaki Itamochi; Nao Oumi; Tetsuro Oishi; Tadahiro Shoji; Hiroyuki Fujiwara; Toru Sugiyama; Mitsuaki Suzuki; Junzo Kigawa; Tasuku Harada
Journal:  Int J Clin Oncol       Date:  2015-03-06       Impact factor: 3.402

9.  Loss of ARID1A Expression in Gastric Cancer: Correlation with Mismatch Repair Deficiency and Clinicopathologic Features.

Authors:  Kyung-Ju Kim; Hae Yoen Jung; Mee-Hye Oh; Hyundeuk Cho; Ji-Hye Lee; Hyun Ju Lee; Si-Hyong Jang; Moon Soo Lee
Journal:  J Gastric Cancer       Date:  2015-09-30       Impact factor: 3.720

Review 10.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.